Divalproex Sodium Market Report
The report on the Divalproex Sodium Market is segmented By Form (Capsule, Tablet, Syrup), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Epilepsy, Manic Depressive Illness, Others) and Region. It also covers the COVID-19 Impact Analysis and Forecast to 2026. This market research report provides an in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global divalproex sodium market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The report on the Divalproex Sodium Market is segmented By Form (Capsule, Tablet, Syrup), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Epilepsy, Manic Depressive Illness, Others) and Region. ...
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Divalproex Sodium Market is estimated to grow from USD 2.1 billion in 2020 to USD 3.0 billion by 2026 at a healthy CAGR of 6.2% during the forecast period.
Divalproex sodium is a Food and Drug Administrator (FDA) approved anti-epileptic drug which is used to treat migraine headaches, certain types of seizures, and manic episodes of bipolar disorders. It is widely known for its anti-convulsant properties for the treatment of epilepsy. It is also used in various combinational therapies.
Key players operating in the divalproex sodium market are-
Growing prevalence of bipolar disorders across the globe is augmenting the divalproex sodium market growth.
Based on application, the divalproex sodium market is classified into epilepsy, manic depressive illness, and others.
By region, the North America market accounted for the largest share in 2020 and is expected to grow at a substantial CAGR in the following years.
The COVID-19 outbreak has moderately affected the divalproex sodium industry. This is mainly attributed to shift of medical care towards coronavirus infected patients. However, rising cases of bipolar disorder due to stress during the pandemic, is expected to surge the product demand amid the pandemic.
Here is the list of the group of customers that the Divalproex Sodium market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The divalproex sodium market size is expected to reach USD 3.0 billion in the foreseeable future.
AbbVie (The U.S), Mylan, Zydus Pharms USA, Aurobindo Pharma (India), Dr Reddys Labs (India), LUPIN (India), Orchid (India), Sun Pharm (India) and Teva (Israel) are among the key players in the divalproex sodium market.
The divalproex sodium market is expected to witness an impressive growth of 6.2% CAGR in the coming years.
The epilepsy segment is expected to grow at the highest CAGR in the divalproex sodium market in the coming years.
North America market accounted for the largest share in 2020 and is expected to grow at a substantial CAGR.
Divalproex sodium vendors, Divalproex sodium retailers, Epilepsy organizations, Psychiatrists are the target audience in the divalproex sodium market.